1. Report Introduction 2. Alpha Antitrypsin Deficiency Epidemiology Overview at a Glance 2.1. Prevalent Population of Alpha Antitrypsin Deficiency in 2016 2.2. Prevalent Population of Alpha Antitrypsin Deficiency in 2027 3. Disease Background and Overview: Alpha Antitrypsin Deficiency 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Genetic Inheritance of Alpha Antitrypsin Deficiency 3.6. Pathophysiology 3.7. Complications 3.8. Diagnosis 3.9. Treatment 3.10. Diagnostic Delay 4. Epidemiology and Patient Population 4.1. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM 4.2. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM – By Region 4.3. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM – Distribution (2016) 4.4. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM – Distribution (2027) 4.5. Epidemiology of Alpha-1-Antitrypsin Deficiency- By Country 4.5.1. United States 4.5.1.1. Assumptions and Rationale 4.5.1.2. Population at risk of Alpha Antitrypsin Deficiency in United States 4.5.1.3. Prevalent Population of Alpha Antitrypsin Deficiency 4.5.2. EU5 4.5.2.1. Assumptions and Rationale 4.5.2.2. Germany 4.5.2.2.1. Population at risk of Alpha Antitrypsin Deficiency in Germany 4.5.2.2.2. Prevalent Population of Alpha Antitrypsin Deficiency in Germany 4.5.2.3. France 4.5.2.3.1. Population at risk of Alpha Antitrypsin Deficiency in France 4.5.2.3.2. Prevalent Population of Alpha Antitrypsin Deficiency in France 4.5.2.4. Italy 4.5.2.4.1. Population at risk of Alpha Antitrypsin Deficiency in Italy 4.5.2.4.2. Prevalent Population of Alpha Antitrypsin Deficiency in Italy 4.5.2.5. Spain 4.5.2.5.1. Population at risk of Alpha Antitrypsin Deficiency in Spain 4.5.2.5.2. Prevalent Population of Alpha Antitrypsin Deficiency in Spain 4.5.2.6. United Kingdom 4.5.2.6.1. Population at risk of Alpha Antitrypsin Deficiency in UK 4.5.2.6.2. Prevalent Population of Alpha Antitrypsin Deficiency in UK 4.5.3. Japan 4.5.3.1. Diagnosed Population of Alpha Antitrypsin Deficiency in Japan 5. Appendix 6. Report Methodology 6.1. Sources Used 7. Consulting Services 8. Disclaimer 9. About DelveInsight

Table 1: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2016-2027) Table 2: Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM (2016-2027) Table 3: Population at risk of Alpha Antitrypsin Deficiency in United States (2016-2027) Table 4: Prevalent Population of Alpha Antitrypsin Deficiency in United States (2016-2027) Table 5: Population at risk of Alpha Antitrypsin Deficiency in Germany (2016-2027) Table 6: Prevalent Population of Alpha Antitrypsin Deficiency in Germany (2016-2027) Table 7: Population at risk of Alpha Antitrypsin Deficiency in France (2016-2027) Table 8: Prevalent Population of Alpha Antitrypsin Deficiency in France (2016-2027) Table 9: Population at risk of Alpha Antitrypsin Deficiency in Italy (2016-2027) Table 10: Prevalent Population of Alpha Antitrypsin Deficiency in Italy (2016-2027) Table 11: Population at risk of Alpha Antitrypsin Deficiency in Spain (2016-2027) Table 12: Prevalent Population of Alpha Antitrypsin Deficiency in Spain (2016-2027) Table 13: Population at risk of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027) Table 14: Prevalent Population of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027) Table 15: Diagnosed Population of Alpha Antitrypsin Deficiency in Japan (2016-2027) Figure 1: Pathogenesis of Alpha Antitrypsin Deficiency Figure 2: Diagnostic Algorithm of Alpha Antitrypsin Deficiency Figure 3: General Treatment of Alpha Antitrypsin Deficiency Figure 4: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2016-2027) Figure 5: Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM (2016-2027) Figure 6: Population at risk of Alpha Antitrypsin Deficiency in United States (2016-2027) Figure 7: Prevalent Population of Alpha Antitrypsin Deficiency in United States (2016-2027) Figure 8: Population at risk of Alpha Antitrypsin Deficiency in Germany (2016-2027) Figure 9: Prevalent Population of Alpha Antitrypsin Deficiency in Germany (2016-2027) Figure 10: Population at risk of Alpha Antitrypsin Deficiency in France (2016-2027) Figure 11: Prevalent Population of Alpha Antitrypsin Deficiency in France (2016-2027) Figure 12: Population at risk of Alpha Antitrypsin Deficiency in Italy (2016-2027) Figure 13: Prevalent Population of Alpha Antitrypsin Deficiency in Italy (2016-2027) Figure 14: Population at risk of Alpha Antitrypsin Deficiency in Spain ( (2016-2027) Figure 15: Prevalent Population of Alpha Antitrypsin Deficiency in Spain (2016-2027) Figure 16: Population at risk of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027) Figure 17: Prevalent Population of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027) Figure 18: Diagnosed Population of Alpha Antitrypsin Deficiency in Japan (2016-2027)